StemCells Inc. has completed enrolment in the Company’s Phase I/II clinical trial in spinal cord injury. The multi-national Phase I/II trial is evaluating both safety and preliminary efficacy of the company’s HuCNS-SC® human neural stem cells as a treatment for chronic spinal cord injury.
The trial enrolled twelve subjects with chest-level injury to the spinal cord. The trial enrolled seven patients with complete paralysis, no motor or sensory function below the point of injury, classified as complete (AIS A), and five patients with no motor function and limited sensory function below the point of injury classified as incomplete (AIS B).
An interim update based on six month data for the first six subjects at the American Spinal Injury Association conference is due in May. Final results are expected mid-2015.